Main Menu

Cancer Genetics, Inc.



Attention investors who purchased shares of Cancer Genetics, Inc. before August 24, 2020:

Rigrodsky & Long is investigating potential claims against the board of directors of Cancer Genetics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to merge with StemoniX, Inc.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating Cancer Genetics, Inc. (“Cancer Genetics”) (NASDAQ CM: CGIX) regarding possible breaches of fiduciary duties and other violations of law related to Cancer Genetics’ agreement to merge with StemoniX, Inc. (“StemoniX”). Under the terms of the agreement, Cancer Genetics will issue a number of shares of Cancer Genetics common stock to StemoniX shareholders.

If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at 

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page